Granmolusco

8 posts

Granmolusco

Granmolusco

@Granmolus7

Katılım Nisan 2026
16 Takip Edilen1 Takipçiler
Granmolusco
Granmolusco@Granmolus7·
$Rave $30 @chartexpt @RaveDAO @ufukless1 gracias por esto gran proyecto, espero siga subiendo muchos más, no voy en contra de la corriente por eso no lo vendo en corto, precio esperado para mi $30 me haría muy feliz, bendiciones y gracias
Granmolusco tweet media
Español
2
0
1
123
PENG.O
PENG.O@PengMacro·
$RAVE 价格再次回到18.88 还有没有空军勇士?
PENG.O tweet media
中文
1
0
0
92
Granmolusco
Granmolusco@Granmolus7·
$Rave $20 y mucho más alto @RaveDAO gracias por una nueva entrega
Granmolusco tweet media
Español
0
0
0
108
Granmolusco retweetledi
DeFi PANDA 🐼
DeFi PANDA 🐼@DeFi_Paanda·
$BIO @Bioprotocol looks ready to pull god candle, pull it, thank u @paulkhls . DeSci leader trading at sub 50million cap? Leader in AI in Billion, Leader in DeFi in Billion.
DeFi PANDA 🐼 tweet media
English
12
12
80
45.5K
Granmolusco retweetledi
Bio Protocol
Bio Protocol@BioProtocol·
Drug-naive ADHD patients show measurably lower orexin-A/B levels. OX2R is the receptor that drives arousal and attention. No approved drug activates it. Every orexin therapy on the market does the opposite. @BioProtocol's scientific team and @peptai_ developed OX2R-004, a selective peptide agonist targeting exactly this gap, and ran it through the full 8-gate computational pipeline over 24 hours on @BioProtocol infrastructure. It cleared most gates: Clean binding geometry, zero immunogenicity signals, toxicity score 0.0. Two known failure points remain but both have standard peptide engineering fixes. First wet-lab validation costs $500. Traditional pharma spends years and tens of millions to reach this same checkpoint. The modality is open, the biology is solid, and the barrier to entry just collapsed.
Paul Kohlhaas bio/acc@paulkhls

🧵 Over 24 hours, our scientific team and AI scientist infrastructure developed a novel peptide agonist to potentially treat ADHD. Below is our paper for a pre-IND computational feasibility assessment for OX2R-004: an 18-residue peptide agonist designed as a selective OX2R agonist for ADHD. Why this matters? No approved orexin agonists exist anywhere. All marketed orexin drugs are dual OX1R/OX2R antagonists for insomnia. Clinical-stage ones are small molecules for narcolepsy only. We did this with @peptai_ a novel full 8-gate computational pipeline in one shot developed by @BioProtocol community 👇

English
26
29
172
25.3K